LaFleur & Godfrey LLC Has $4.40 Million Position in Medtronic PLC $MDT

LaFleur & Godfrey LLC lifted its position in shares of Medtronic PLC (NYSE:MDT) by 15.6% in the third quarter, HoldingsChannel.com reports. The fund owned 46,154 shares of the medical technology company’s stock after buying an additional 6,218 shares during the period. LaFleur & Godfrey LLC’s holdings in Medtronic were worth $4,396,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Marks Group Wealth Management Inc lifted its stake in Medtronic by 2.3% during the third quarter. Marks Group Wealth Management Inc now owns 29,497 shares of the medical technology company’s stock worth $2,809,000 after purchasing an additional 671 shares during the last quarter. Washington Trust Advisors Inc. raised its holdings in shares of Medtronic by 15.9% during the 3rd quarter. Washington Trust Advisors Inc. now owns 853 shares of the medical technology company’s stock worth $81,000 after buying an additional 117 shares in the last quarter. Quantum Private Wealth LLC lifted its position in shares of Medtronic by 18.0% during the 3rd quarter. Quantum Private Wealth LLC now owns 3,021 shares of the medical technology company’s stock worth $288,000 after buying an additional 461 shares during the last quarter. Vestmark Advisory Solutions Inc. lifted its position in shares of Medtronic by 9.9% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 17,659 shares of the medical technology company’s stock worth $1,682,000 after buying an additional 1,592 shares during the last quarter. Finally, Westerkirk Capital Inc. boosted its stake in Medtronic by 49.7% in the third quarter. Westerkirk Capital Inc. now owns 10,578 shares of the medical technology company’s stock valued at $1,007,000 after buying an additional 3,510 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on MDT. Morgan Stanley boosted their target price on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday. Sanford C. Bernstein raised their target price on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Finally, Needham & Company LLC dropped their price target on Medtronic from $121.00 to $120.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $110.84.

Medtronic Price Performance

MDT stock opened at $96.88 on Monday. The company has a market capitalization of $124.20 billion, a P/E ratio of 26.99, a PEG ratio of 2.43 and a beta of 0.71. The company has a fifty day moving average price of $99.04 and a 200-day moving average price of $96.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.Medtronic’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is currently 79.11%.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).